Rocher I, Decourt S, Leneveu A, Lebrec D, Rosier S P, Flouvat B
Int J Clin Pharmacol Ther Toxicol. 1985 Aug;23(8):406-10.
The pharmacokinetic properties of propranolol and atenolol were evaluated both in 9 patients with cirrhosis and in 12 healthy subjects. The hemodynamic effects of the drugs were evaluated separately in the cirrhotic patients. Propranolol and atenolol significantly decreased wedged hepatic venous pressure and cardiac output in cirrhotic patients. Propranolol Cmax, tmax and AUC were significantly increased and plasma half-life was significantly prolonged in cirrhotic patients. In contrast, the corresponding pharmacokinetic values of atenolol were not significantly different in cirrhotic patients and in healthy subjects.
在9例肝硬化患者和12名健康受试者中评估了普萘洛尔和阿替洛尔的药代动力学特性。在肝硬化患者中分别评估了这些药物的血流动力学效应。普萘洛尔和阿替洛尔显著降低了肝硬化患者的肝静脉楔压和心输出量。肝硬化患者中普萘洛尔的Cmax、tmax和AUC显著升高,血浆半衰期显著延长。相比之下,阿替洛尔在肝硬化患者和健康受试者中的相应药代动力学值无显著差异。